English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

A group of 160 patients with primary glioblastoma treated with radiotherapy and temozolomide was analyzed for the impact of  O6-methly-guanly-methyl-transferase  ( MGMT) -promoter methylation as well as  isocitrate dehydrogenase (IDH)1 -mutational status. Unexpectedly, overall survival or progression-free survival were not longer in the group with methylated  MGMT -promoter as compared to patients without that methylation.  IDH-1  mutations were significantly associated with increased overall survival.

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?